Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Research and development - MRTP

Sales, general and administrative

Impairment of intangible assets

Depreciation

Amortization

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

22nd Century Group

22nd Century Group, Inc. is a biotechnology company, which develops disruptive plant-based solutions the for life science, consumer product, and pharmaceutical markets. It focuses on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp or cannabis plants through genetic engineering, gene-editing, and modern plant breeding techniques. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

22nd Century Group advances VLN and GVB units towards profitability

22nd Century Group's Q4 2022 earnings call highlighted progress in VLN tobacco and GVB hemp/cannabis units, with plans for multi-state launches and cash positive operations in 2024. Despite challenges like the Grass Valley facility fire, the company remains focused on achieving profitability through revenue growth and market expansion. Key strengths include successful pilot results, volume growth, and a clear path to cash positivity for both business units.

22nd Century Group (XXII) reports strong Q1 performance and growth strategies

22nd Century Group (XXII) showcases strong performance and strategic initiatives to drive revenue growth and achieve cash positivity by 2024.
Despite challenges such as analyst inquiries and insurance impacts, the company's focus on cost efficiencies and margin improvements positions it for success.
Opportunities in revenue growth, bulk ingredient capacity expansion, and margin enhancements present promising prospects for future profitability and market growth.

22nd Century Group reports strong Q2 performance amidst operational challenges

22nd Century Group's Q2 performance showcased growth in sales but faced challenges in gross profit due to production mix shifts.
The company's proactive strategies for cost savings, brand value creation, and gross margin improvement indicate a focus on long-term sustainability.
Despite challenges like VLN rollout delays and tobacco business hurdles, opportunities in market differentiation and efficiency improvements are being pursued.

22nd Century Group pursues profitability through strategic shifts and cost management

22nd Century Group's Q4 2023 earnings call highlighted efforts to achieve profitability by reducing cash burn, focusing on VLN cigarettes for harm reduction, and exploring CMO opportunities in tobacco manufacturing. Despite challenges like decreased net sales and a negative gross profit, the company aims to reach breakeven by Q1 2025.

22nd Century Group reduces cash burn, aims for profitability by 2025

22nd Century Group's Q1 2024 performance reflects progress towards profitability, with improved financial discipline and operational efficiency.
While facing revenue challenges and legal disputes, the company's strategic initiatives and investor support position it for future growth and success.
The focus on reducing losses, strengthening the balance sheet, and expanding market presence underscores the company's commitment to long-term sustainability.

22nd Century Group reports Q2 financial turnaround and growth strategies

22nd Century Group's Q2 2024 performance reflects a notable financial turnaround and progress towards profitability.
Strategic initiatives, leadership appointments, and product strategies position the company for future growth and success.
While challenges remain in achieving cash positive operations, opportunities in market expansion and product innovation offer avenues for continued advancement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

22nd Century Group, Inc. is a biotechnology company, which engages in the business of tobacco harm reduction, reduced nicotine tobacco, and improvement of health and wellness through plant science. It operates through the Tobacco and Hemp/Cannabis segments. The Tobacco segment manufactures branded filtered cigars and cigarettes. The Hemp/Cannabis segment focuses on the bulk ingredient distillate or isolate. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.

Another key indicator and milestone of the Increasing Importance of Reducing Cigarette Nicotine Content as Cornerstone of Public Health Policy Another key indicator and milestone of the Increasing Importance of Reducing Cigarette Nicotine Content as Cornerstone of Public Health Policy

22nd Century Group Regulatory Science VP Joins FDLI Tobacco and Nicotine Products Committee

Want to bet on rising stars in the $61 billion U.S. marijuana industry? Here are the top picks.

3 Best Emerging Marijuana Stocks to Buy in April

WILLIAMSVILLE, N.Y., April 01, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that it continues to be confident on the renewal of the FDA's proposed reduced nicotine mandate that would make all cigarettes “minimally or non-addictive.” By way of support, four former U.S. Food and Drug Administration (FDA) commissioners, Robert M. Califf, M.D. MACC; Scott Gottlieb, M.D.; Peggy Hamburg, M.D.; and, Jane Henney, M.D., spoke on a recent panel and were vocal in their endorsement of the mandate to limit the amount of nicotine in cigarettes to levels already achieved by 22nd Century's reduced nicotine content cigarettes, VLN® .

Multiple Former FDA Commissioners Voice Support for Reduced Nicotine Mandate; Proposed Legislation Would Be Game-Changing for 22nd Century

Greenlane Holdings

GrowGeneration Corp

Akerna Corp

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will continue to develop in the 2021.

NY Inches Toward Legalization, Plus 4 Pot Stocks are Blazing

XXII is awaiting MRTP authorization from the FDA and, once granted, the company will bring to market its VLN cigarettes. The company is also positioned, via its partnerships, to introduce its high THC cannabis genetics to the market.

22nd Century Group Positioned For Growth In Cannabis And Tobacco Markets

Management seems confident of MRTP approval. The VLN cigarette has no real competition in the combustible space.

22nd Century Group: Why We Use Options For Upcoming, Game-Changing MRTP Binary Event

Confirmation of Becerra as New HHS Secretary May Reignite FDA's Plan to Eliminate Addictive Cigarettes Confirmation of Becerra as New HHS Secretary May Reignite FDA's Plan to Eliminate Addictive Cigarettes

Becerra Confirmation Boosts 22nd Century's Position to Disrupt Tobacco Industry

Investors need to pay close attention to 22nd Century (XXII) stock based on the movements in the options market lately.

Do Options Traders Know Something About 22nd Century (XXII) Stock We Don't?

Tobacco and marijuana bioengineering? Yeah, that's apparently a thing now.

Why 22nd Century Group Stock Just Lit Up

WILLIAMSVILLE, N.Y., March 12, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, today announced that it has received an additional $3.7 million, for total net proceeds of $11.8 million, from the completion of the cash exercise of warrants during February and March of 2021. Following this transaction, the Company is free of any outstanding warrants.

22nd Century Group Receives Additional $3.7 Million from Cash Exercise of Outstanding Warrants

22nd Century Group's (XXII) CEO Jim Mish on Q4 2020 Results - Earnings Call Transcript

22nd Century Group Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2020

Arena Pharmaceuticals

New Age Beverages

4 Cannabis Stocks in the News This Week

WILLIAMSVILLE, N.Y., March 05, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, today announced that members of its management team will participate in three investor conferences during March 2021.

22nd Century Group to Participate in Investor Conferences in March 2021

22nd Century (XXII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will 22nd Century Group (XXII) Report Negative Earnings Next Week? What You Should Know

WILLIAMSVILLE, N.Y., March 04, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, today announced that it has received net proceeds of $8.1 million from the cash exercise of outstanding warrants during February and March of 2021. The remaining warrants, if exercised for cash, will bring additional net proceeds of $3.7 million in cash to the Company. Following the above transaction, the Company will no longer have any outstanding warrants.

22nd Century Group Receives $8.1 Million from Cash Exercise of Outstanding Warrants

WILLIAMSVILLE, N.Y., Feb. 25, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, will host a live audio webcast on Thursday, March 11, 2020, at 8:00 a.m. Eastern Standard Time to discuss its 2020 fourth quarter and full-year results. 22nd Century will report the Company's fourth quarter and full-year 2020 results in a press release at 7:00 a.m. Eastern Standard Time the same day.

22nd Century Group to Host Webcast to Discuss Fourth Quarter and Full-Year 2020 Results

Global Commercial Opportunities in Approximately +$800 Billion Markets Across Tobacco and Hemp/Cannabis Global Commercial Opportunities in Approximately +$800 Billion Markets Across Tobacco and Hemp/Cannabis

22nd Century Group Provides Business Update Letter from CEO

Breakthrough expected to yield disruptive plant lines and new licensing opportunities with strategic partners Breakthrough expected to yield disruptive plant lines and new licensing opportunities with strategic partners

22nd Century Group and KeyGene Launch Advanced Cannabis Technology Platform for Accelerated Development of New Varieties of Hemp/Cannabis Plants with Commercially Valuable Traits

Aurora Cannabis

Aphria

FSD Pharma

Innovative Industrial Properties

Tilray Brands

cbdMD Inc

Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will develop in the 2021.

8 Pot Stocks in Focus Amid the WallStreetBets Frenzy

New space is ideally equipped and located in the heart of Buffalo's urban renewal New space is ideally equipped and located in the heart of Buffalo's urban renewal

22nd Century Group to Relocate Headquarters to Buffalo's Thriving Larkinville District

The FDA Can Save 8 Million Lives and Prevent 1,600 Kids From Becoming Addicted Every Day The FDA Can Save 8 Million Lives and Prevent 1,600 Kids From Becoming Addicted Every Day

The Buffalo News Op-ed: 22nd Century CEO Urges FDA to Proceed with Plan to Limit Nicotine Levels in Cigarettes

WILLIAMSVILLE, N.Y., Jan. 19, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today the dismissal with prejudice of the federal securities class action lawsuit captioned Noto. V. 22nd Century Group, Inc., 19-CV-1285 by a federal district court in the Western District of New York on January 14, 2021. The case was initially filed in the Eastern District of New York, where it was captioned Bull v. 22nd Century Group, Inc. 1:19-CV-00409. In denying the Plaintiffs' request for an opportunity to file another amended Complaint, the Court held that “further amendment would be futile.”

Federal Court Dismisses Securities Class Action Lawsuit Against 22nd Century Group

New intellectual property facilitates the precise control and modulation of cannabinoid production New intellectual property facilitates the precise control and modulation of cannabinoid production

22nd Century Group Achieves Breakthrough Hemp/Cannabis GMO Technology; Granted New Patent for Controlling Genes Responsible for Production of CBD, THC, and Other Valuable Cannabinoids

News for 22nd Century Group Stock (XXII)